Agampodi Suneth, Tadesse Birkneh Tilahun, Sahastrabuddhe Sushant, Excler Jean-Louis, Kim Jerome Han
Innovation, Initiatives and Enterprise Development Unit, International Vaccine Institute, Seoul, Republic of Korea.
Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, United States.
Front Med (Lausanne). 2024 Oct 30;11:1474045. doi: 10.3389/fmed.2024.1474045. eCollection 2024.
Observational studies on COVID-19 vaccine effectiveness (VE) have provided critical real-world data, informing public health policy globally. These studies, primarily using pre-existing data sources, have been indispensable in assessing VE across diverse populations and developing sustainable vaccination strategies. Cohort design is frequently employed in VE research. The rapid implementation of vaccination campaigns during the COVID-19 pandemic introduced differential vaccination influenced by sociodemographic disparities, public policies, perceived risks, health-promoting behaviors, and health status, potentially resulting in biases such as healthy user bias, healthy vaccinee effect, frailty bias, differential depletion of susceptibility bias, and confounding by indication. The overwhelming burden on healthcare systems has escalated the risk of data inaccuracies, leading to outcome misclassifications. Additionally, the extensive array of diagnostic tests used during the pandemic has also contributed to misclassification biases. The urgency to publish quickly may have further influenced these biases or led to their oversight, affecting the validity of the findings. These biases in studies vary considerably depending on the setting, data sources, and analytical methods and are likely more pronounced in low- and middle-income country (LMIC) settings due to inadequate data infrastructure. Addressing and mitigating these biases is essential for accurate VE estimates, guiding public health strategies, and sustaining public trust in vaccination programs. Transparent communication about these biases and rigorous improvement in the design of future observational studies are essential.
关于新冠病毒疫苗有效性(VE)的观察性研究提供了关键的真实世界数据,为全球公共卫生政策提供了信息。这些研究主要利用现有的数据来源,对于评估不同人群的疫苗有效性以及制定可持续的疫苗接种策略不可或缺。队列设计在疫苗有效性研究中经常被采用。在新冠疫情期间疫苗接种活动的迅速开展引入了受社会人口统计学差异、公共政策、感知风险、健康促进行为和健康状况影响的差异接种,这可能导致诸如健康使用者偏差、健康接种者效应、虚弱偏差、易感性偏差的差异耗竭以及指示性混杂等偏差。医疗系统的巨大负担增加了数据不准确的风险,导致结果错误分类。此外,疫情期间使用的大量诊断测试也导致了错误分类偏差。快速发表的紧迫性可能进一步影响了这些偏差或导致对它们的忽视,影响了研究结果的有效性。这些研究中的偏差因研究背景、数据来源和分析方法的不同而有很大差异,并且由于数据基础设施不足,在低收入和中等收入国家(LMIC)环境中可能更为明显。解决和减轻这些偏差对于准确估计疫苗有效性、指导公共卫生策略以及维持公众对疫苗接种计划的信任至关重要。关于这些偏差的透明沟通以及未来观察性研究设计的严格改进至关重要。